SEPN

+ Watchlist + Portfolio

Septerna, Inc.

Regulated industry Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $38.05
52-Week Range: $17.55 – $51.10
Market Cap: $1.76B
P/E (TTM): —
EPS (TTM): -0.54
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 4.45
PEG Ratio: —
Return on Equity: -6.34%
Return on Assets: -7.13%
Gross Margin: 100.00%
Operating Margin: -62.95%
Profit Margin: -24.51%
Current Ratio: 5.00
Debt/Equity: 0.06
Total Debt: $22.55M
Free Cash Flow: $29.54M
Revenue Growth: 22375.60%
Earnings Growth: —
Enterprise Value: $1.41B

SEPN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$151.00K	$1.07M	$45.95M
Research & Development	$22.04M	$35.98M	$65.34M	$97.58M
Selling, General & Admin	$5.92M	$9.72M	$16.56M	$29.16M
Operating Expenses	$27.97M	$45.70M	$81.90M	$126.75M
Operating Income	-$27.97M	-$45.55M	-$80.82M	-$80.80M
EBITDA	-$27.39M	-$44.70M	-$79.42M	-$79.19M
Pretax Income	-$27.68M	$4.87M	-$72.30M	-$48.87M
Income Tax	$0.00	$691.00K	-$498.00K	$12.00K
Net Income	-$27.68M	$4.18M	-$71.80M	-$48.88M
Diluted EPS	-1.42	0.03	-7.26	-1.10
Diluted Shares	19.50M	19.50M	9.89M	44.26M

SEPN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$30.61M	$88.48M	$238.20M	$120.72M
Receivables	$0.00	$22.78M	$1.12M	$13.74M
Current Assets	$31.89M	$112.68M	$356.82M	$410.96M
Total Assets	$36.12M	$130.87M	$456.55M	$596.19M
Current Liabilities	$5.54M	$6.91M	$12.85M	$86.93M
Total Debt	$710.00K	$12.57M	$25.48M	$23.63M
Total Liabilities	$80.32M	$169.24M	$36.51M	$214.26M
Retained Earnings	-$50.76M	-$46.58M	-$118.37M	-$167.25M
Shareholders' Equity	-$44.20M	-$38.37M	$420.05M	$381.93M
Working Capital	$26.35M	$105.76M	$343.98M	$324.03M

SEPN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$23.30M	-$38.72M	-$67.47M	$110.19M
Capital Expenditure	-$1.29M	-$2.88M	-$2.10M	-$518.00K
Free Cash Flow	-$24.59M	-$41.60M	-$69.57M	$109.67M
Depreciation & Amortisation	$577.00K	$848.00K	$1.40M	$1.60M
Stock-Based Compensation	$1.52M	$1.62M	$3.15M	$8.48M
Investing Cash Flow	-$1.29M	$22.12M	-$160.60M	-$229.35M
Financing Cash Flow	$30.05M	$74.52M	$377.78M	$1.69M
Share Repurchases	—	-$1.00K	-$1.00K	-$1.00K
Net Change in Cash	$5.46M	$57.92M	$149.71M	-$117.47M

SEPN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$219.00K	$119.00K	$21.50M	$24.12M	$26.52M	$26.75M
Research & Development	$19.27M	$22.19M	$24.26M	$31.86M	$29.54M	$35.13M
Selling, General & Admin	$6.86M	$6.91M	$7.12M	$8.28M	$10.29M	$8.45M
Operating Expenses	$26.13M	$29.10M	$31.38M	$40.14M	$39.82M	$43.58M
Operating Income	-$25.91M	-$28.98M	-$9.89M	-$16.02M	-$13.30M	-$16.84M
EBITDA	-$25.51M	-$28.57M	-$9.48M	-$15.62M	-$12.88M	-$16.41M
Pretax Income	-$21.48M	-$24.84M	$8.17M	-$10.73M	-$8.30M	-$12.06M
Income Tax	$0.00	$0.00	$0.00	$12.00K	$337.00K	$973.00K
Net Income	-$21.48M	-$24.84M	$8.17M	-$10.74M	-$8.64M	-$13.03M
Diluted EPS	-0.49	-0.56	0.18	-0.24	-0.19	-0.29
Diluted Shares	43.94M	44.17M	45.60M	44.58M	44.76M	45.04M

SEPN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$210.04M	$189.31M	$319.99M	$120.72M	$71.61M	$84.66M
Receivables	$1.33M	$2.57M	$11.72M	$13.74M	$14.29M	$15.94M
Current Assets	$342.47M	$334.14M	$491.68M	$410.96M	$368.06M	$396.15M
Total Assets	$434.02M	$415.23M	$606.65M	$596.19M	$569.69M	$566.74M
Current Liabilities	$10.64M	$15.13M	$75.28M	$86.93M	$78.17M	$79.32M
Total Debt	$25.03M	$24.57M	$24.11M	$23.63M	$23.09M	$22.55M
Total Liabilities	$33.75M	$37.67M	$217.92M	$214.26M	$191.23M	$180.02M
Retained Earnings	-$139.85M	-$164.69M	-$156.51M	-$167.25M	-$175.89M	-$188.92M
Shareholders' Equity	$400.27M	$377.56M	$388.73M	$381.93M	$378.46M	$386.72M
Working Capital	$331.83M	$319.01M	$416.40M	$324.03M	$289.89M	$316.84M

SEPN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$23.34M	-$20.29M	$168.81M	-$14.99M	-$25.63M	-$22.18M
Capital Expenditure	-$382.00K	-$58.00K	-$13.00K	-$65.00K	-$832.00K	—
Free Cash Flow	-$23.73M	-$20.34M	$168.79M	-$15.05M	-$26.46M	-$22.18M
Depreciation & Amortisation	$397.00K	$405.00K	$401.00K	$401.00K	$421.00K	$427.00K
Stock-Based Compensation	$1.48M	$1.81M	$2.53M	$2.66M	$6.01M	$5.07M
Investing Cash Flow	-$4.87M	-$786.00K	-$38.39M	-$185.30M	-$23.82M	$18.41M
Financing Cash Flow	$66.00K	$339.00K	$263.00K	$1.02M	$333.00K	$16.82M
Share Repurchases	$0.00	—	—	$0.00	—	—
Net Change in Cash	-$28.15M	-$20.73M	$130.68M	-$199.27M	-$49.12M	$13.06M

Market Snapshot

About

Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing oral small molecule drugs for G protein-coupled receptor targets. The company utilizes a proprietary Native Complex Platform to unlock challenging GPCR targets across various therapeutic areas. Septerna aims to create transformative medicines for patients with significant unmet medical needs.